SEQUENCE LISTING

<110> Claragen, Inc. & NIH

<120> Use of Recombinant Human Uteroglobin in Treatment of Inflammatory and Fibrotic Conditions

<130> 116142-85

<140> to be assigned
<141> 2003-08-22

<150> 09/549,926
<151> 2000-04-14

<160> 12

<170> PatentIn version 3.2

<210> 1
<211> 70
<212> PRT
<213> human

<400> 1

```
Glu Ile Cys Pro Ser Phe Gln Arg Val Ile Glu Thr Leu Leu Met Asp
1               5                  10                  15

Thr Pro Ser Ser Tyr Glu Ala Ala Met Glu Leu Phe Ser Pro Asp Gln
            20                  25                  30

Asp Met Arg Glu Ala Gly Ala Gln Leu Lys Lys Leu Val Asp Thr Leu
        35                  40                  45

Pro Gln Lys Pro Arg Glu Ser Ile Ile Lys Leu Met Glu Lys Ile Ala
    50                  55                  60

Gln Ser Ser Leu Cys Asn
65                  70
```

<210> 2
<211> 69
<212> PRT
<213> rabbit

<400> 2

```
Gly Ile Cys Pro Arg Phe Ala His Val Ile Glu Asn Leu Leu Leu Gly
1               5                  10                  15

Thr Pro Ser Ser Tyr Glu Thr Ser Leu Lys Glu Phe Glu Pro Asp Asp
            20                  25                  30

Thr Met Lys Asp Ala Gly Met Gln Met Lys Lys Val Leu Asp Ser Leu
        35                  40                  45

Pro Gln Thr Thr Arg Glu Asn Ile Met Lys Leu Thr Glu Lys Ile Val
    50                  55                  60

Lys Ser Pro Leu Cys
65
```

<210> 3
<211> 75
<212> PRT
<213> rat

<400> 3

```
Asp Ile Cys Pro Gly Phe Leu Gln Val Leu Glu Ala Leu Leu Leu Gly
1               5                  10                  15

Ser Glu Ser Asn Tyr Glu Ala Ala Leu Lys Pro Phe Asn Pro Ala Ser
            20                  25                  30

Asp Leu Gln Asn Ala Gly Thr Gln Leu Lys Arg Leu Val Asp Thr Leu
        35                  40                  45

Pro Gln Glu Thr Arg Ile Asn Ile Val Lys Leu Thr Glu Lys Ile Leu
    50                  55                  60

Thr Ser Pro Leu Cys Glu Gln Asp Leu Arg Val
65                  70                  75
```

<210> 4
<211> 75
<212> PRT
<213> mouse

<400> 4

Asp Ile Cys Pro Gly Phe Leu Gln Val Leu Glu Ala Leu Leu Met Glu
1 5 10 15

Ser Glu Ser Gly Tyr Val Ala Ser Leu Lys Pro Phe Asn Pro Gly Ser
20 25 30

Asp Leu Gln Asn Ala Gly Thr Gln Leu Lys Arg Leu Val Asp Thr Leu
35 40 45

Pro Gln Glu Thr Arg Ile Asn Ile Met Lys Leu Thr Glu Lys Ile Leu
50 55 60

Thr Ser Pro Leu Cys Lys Gln Asp Leu Arg Phe
65 70 75

<210> 5
<211> 65
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 5
gatccatgga aatctgcccg tctttccagc gtgttatcga aaccctgctg atggacaccc 60

cgtcc 65

<210> 6
<211> 60
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 6
agctacgaag cagctatgga actgttctct ccggaccagg acatgcgtga agcaggtgct 60

<210> 7
<211> 59
<212> DNA
<213> Artificial

<220>

<223> Description of Artificial Sequence: primer sequence

<400> 7
cagctgaaga aactggttga caccctgccg cagaaaccgc gtgaatccat cataaactg 59

<210> 8
<211> 37
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 8
atggagaaga tcgctcagtc tagcctgtgc aactaag 37

<210> 9
<211> 60
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 9
cttagttgca caggctagac tgagcgatct tctccatcag tttgatgatg gattcacgcg 60

<210> 10
<211> 59
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 10
gtttctgcgg cagggtgtca accagtttct tcagctgagc actgcttcac gcatgtcct 59

<210> 11
<211> 60
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 11
ggtccggaga gaacagttcc atagctgctt cgtagctgga cggggtgtcc atcagcaggg 60

<210> 12
<211> 42
<212> DNA
<213> Artificial

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 12
tttcgataac acgctggaaa gacgggcaga tttccatgga tc 42